Think it was viewed from BPO holders as 'more dilution' on the way with $500k to pay to SLA via option conversion & the issue/double issue to SLA if targets are met.
Still looks positive for BPO longer term although I'm expecting some more dilution......Looking for a get in price at the mo but may wait a little longer....
Huge markets if they can getthe bioeffectives happening .....hopefully over the mid-term.
BPO Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held